A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
Public ClinicalTrials.gov record NCT03312907. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Study identification
- NCT ID
- NCT03312907
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 292 participants
Conditions and interventions
Conditions
Interventions
- Belimumab Drug
- Rituximab Drug
- Rituximab-placebo Drug
- Standard therapy (Excluding Immunosuppressants) Drug
- Standard therapy (Including Immunosuppressants) Drug
- Steroid Taper Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2018
- Primary completion
- May 28, 2020
- Completion
- Jul 6, 2021
- Last update posted
- Feb 17, 2025
2018 – 2021
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294 | — |
| GSK Investigational Site | La Mesa | California | 92020 | — |
| GSK Investigational Site | San Leandro | California | 94578 | — |
| GSK Investigational Site | Upland | California | 91786 | — |
| GSK Investigational Site | Denver | Colorado | 80230 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Orlando | Florida | 32806-6264 | — |
| GSK Investigational Site | Tamarac | Florida | 33321 | — |
| GSK Investigational Site | Tampa | Florida | 33613 | — |
| GSK Investigational Site | Tampa | Florida | 33614 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48109-5542 | — |
| GSK Investigational Site | Brighton | Michigan | 48116 | — |
| GSK Investigational Site | Lansing | Michigan | 48910 | — |
| GSK Investigational Site | Lansing | Michigan | 48917 | — |
| GSK Investigational Site | Las Cruces | New Mexico | 88011 | — |
| GSK Investigational Site | Manhasset | New York | 11030 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | New York | New York | 10032 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28204 | — |
| GSK Investigational Site | Vandalia | Ohio | 45377 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73102 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15224 | — |
| GSK Investigational Site | Summerville | South Carolina | 29486 | — |
| GSK Investigational Site | Austin | Texas | 78731 | — |
| GSK Investigational Site | League City | Texas | 77573 | — |
| GSK Investigational Site | Spokane | Washington | 99204 | — |
| GSK Investigational Site | Glendale | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03312907, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03312907 live on ClinicalTrials.gov.